Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today a collaboration with NOF CORPORATION to supply its global clients with NOF's COATSOME® SS Series proprietary ionizable lipids, further enhancing its leading position in providing lipid nanoparticle (LNP)-based drug delivery solutions to the market.
NOF CORPORATION's COATSOME® SS Series offers encapsulation of nucleic acids such as mRNA, siRNA, and pDNA. These proprietary ionizable lipids offer efficient drug delivery into the cytoplasm of cells with higher biodegradability and low toxicity, with controlled targeting to organs such as the liver, spleen, and lymph nodes.
"The combination of NOF's lipid technologies and Phosphorex's experience in developing and scaling LNP-based drug delivery solutions delivers a faster, more cost effective and reproducible outcome for customers," said Jarlath Keating, CEO of Phosphorex. "This integrated approach, combining lipid chemistries with state-of-the-art development and manufacturing processes provides a well characterized platform for customers developing LNP-based therapies."
"This collaboration strengthens both companies' portfolios and industry presence by incorporating LNP material development, formulation development and manufacturing services delivering a comprehensive solution to its combined customer base. With this collaboration NOF and Phosphorex create a highly specialized LNP-focused CDMO with unique capabilities," said Yuji Yamamoto, General Manager of Life Science division of NOF CORPORATION.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!